The recent weeks have produced several large studies on exome sequencing in autism and we have previously commented on three publications which appeared back-to-back in Nature. Here I summarize these findings, which advanced our understanding of the genetic architecture of autism in the light of a recent, equally comprehensive study by Iossifov et al. published in Neuron. The enormous amount of genetic variation and de novo mutations in the human genome reported demonstrate the possibilities and difficulties of exome sequencing studies and require new study design. Up to 10% of cases of autism appear due to de novo mutations, indicating a significant, but modest contribution comparable to the effect of copy number variations.
Study by Iossifov et al., 2012. The authors performed exome sequencing in families with an affected proband and at least one unaffected sibling (quads). After stringent filtering they estimate the burden of de novo mutations and indels, finding an elevated rate of likely gene disrupting mutations in probands (17%) compared to unaffected siblings (8%). The rate of all missense mutations in contrast to the gene-disrupting mutations was comparable in probands and siblings. De novo mutations are common in affected and unaffected individuals and additional criteria are required to distinguish causal from benign de novo mutations. Nevertheless, the rate of gene-disrupting mutations in probands with autism is two-fold higher compared to unaffected siblings, suggesting a modest contribution of these mutations to the overall pathogenesis of autism. The authors further analyze molecular pathways that these genes are implicated in and suggest that many products of genes implicated in autism are functionally associated with the Fragile-X-Mental-Retardation Protein (FMRP). In line with previous studies, they estimate 300-400 autism susceptibility genes.
Five novel candidate genes. In conjunction with the study by Neale et al., O’Roak et al. and Sanders et al., recurrent gene-disrupting mutations have been identified in 5 genes, namely, SCN2A, CHD8, KATNAL2, DYRK1A and POGZ. Among these five genes, only SCN2A and DYRK1A have previously been implicated in neurodevelopmental disorders. SCN2A is well known to the epilepsy community and codes for the alpha-2 subunit of the voltage-gated sodium channel. SCN2A is known to cause Benign Familial Neonatal-Infantile Seizures (BFNIS). It should be pointed out that none of the two probands with autism carrying mutations in SCN2A had seizures and the connection between axon initial segment dysfunction and autism in not clear. DYRK1A codes for the dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A and represents the main candidate gene for intellectual disability in Trisomy 21. The role of the other three genes is not clear. CHD8 codes for chromodomain helicase DNA binding protein 8 involved in chromatin remodeling. POGZ codes for the pogo transposable element with ZNF domain involved in transcriptional regulation. The role of KATNAL2 coding for the katanin p60 subunit A-like 2 is unknown. In summary, given the candidate genes from CNV studies in autism including many genes involved in synapse functions, these are not the candidate genes you would expect. The authors point this out, indicating the lack of overlap in candidate genes from CNV and exome studies in autism.
Common findings in all four studies on exome sequencing in autism. Iossifov et al. summarize that the frequency of de novo mutations is elevated in children with older parents, that de novo gene disrupting mutations are twice as frequent in probands compared to siblings and that the role of all missense mutations in general irrespective of their putative functional role is not significant or marginal. In summary, the role of de novo mutations in autism can be compared to the role of large Copy Number Variations (up to 10% of cases). Given the vast expectations put into exome sequencing studies, these results are disappointing. Theoretical predictions suggest a higher rate of de novo mutations in autism and the reasons for this gap are as yet unknown. In addition, these studies highlight the difficulties to distinguish pathogenic from accidental variation, an issue that will be central to the upcoming studies in epilepsy research.
Implication for epilepsy genetics and EuroEPINOMICS. The autism studies provide a template for the EuroEPINOMICS projects, particularly the studies, which sequence probands and parents (trios). In contrast to the “naive” assumption that a causative mutation can be identified in every patient, it will be difficult to tell the pathogenic mutation from benign variation. Assuming that the genetics of various epilepsies is comparable to the genetic architecture of autism, the pathogenic role of identified variants would need to be shown through (a) identification of genes already implicated in neurological disorders, (b) functional studies or (c) statistical evidence. Functional studies will be difficult to implement unless the identified genes fall within pathways for which functional assays are established (e.g. ion channels) and statistical evidence, demonstrating that de novo mutations in a given gene are associated with epilepsy will require large cohorts. From the autism studies, we can expect that using a trio-based design, we will identify likely pathogenic de novo mutations in 10% of probands with epilepsy. Exome sequencing is not the final genetic study that will identify the genetic basis of the majority of patients, but only the beginning for upcoming genome-wide sequencing methods with increasing coverage of the genome that can be interpreted in the presence of a growing body of exome data for neurodevelopmental disorders including autism and intellectual disability. The pick-up rate for other study designs including sequencing of families and sibling pairs is difficult to estimate. However, exome sequencing studies have been particularly successful in this field of genetics.
Some may argue that the outlook for epilepsy studies is rather bleak given the low expected frequency. We don’t. If some similarities between autism, ID and epilepsy are present, exome sequencing studies using a trio-based design have the unique possibility to detect causative mutations in up to 10% of patients and significantly enhance our understanding of various epilepsy syndromes. The prerequisite for these studies, however, is careful phenotyping and biobanking for follow-up studies and further increase in the sequence data generation and processing.
Pingback: Gene birth in yeast and human | EuroEPINOMICS
Pingback: The meeting of the 1000 exomes | EuroEPINOMICS
Pingback: Of steel mills and exomes – the Luxembourg data analysis meeting | EuroEPINOMICS
Pingback: The years of our fathers: paternal age and the rate of de novo mutations | EuroEPINOMICS
Pingback: A little clonazepam to rescue behavioral deficits in SCN1A-deficient mice | EuroEPINOMICS
Pingback: Standing on the shoulders of giants: the EPICURE GWAS on Idiopathic Generalized Epilepsy | EuroEPINOMICS
Pingback: Close encounters of the third kind – rare genetic variants in families | Beyond the Ion Channel
Pingback: De novo mutations in severe intellectual disability | Beyond the Ion Channel
Pingback: Exome sequencing in epileptic encephalopathies – the powers that be | Beyond the Ion Channel
Pingback: The Biobank Dilemma | Beyond the Ion Channel
Pingback: De novo mutations in severe intellectual disability | channelopathist_testing
Pingback: Close encounters of the third kind – rare genetic variants in families | channelopathist_testing
Pingback: De novo mutations in Infantile Spasms and Lennox-Gastaut Syndrome | Beyond the Ion Channel
Pingback: Red Johanna Day – The signal and the noise | Beyond the Ion Channel
Pingback: Recessive mutations in autism – the return of hidden metabolic disorders | Beyond the Ion Channel
Pingback: 5 good reasons for neuroblogging – The EuroEPINOMICS blog celebrates its first birthday | Beyond the Ion Channel
Pingback: Cold fusion – joining exome datasets to identify autism genes | Beyond the Ion Channel
Pingback: Exome sequencing in epileptic encephalopathies – a classification of de novo mutations | Beyond the Ion Channel
Pingback: Less is more – gene identification in epileptic encephalopathies through targeted resequencing | Beyond the Ion Channel
Pingback: Epileptic encephalopathies: de novo mutations take center stage | Beyond the Ion Channel
Pingback: Dravet Syndrome and rare variants in SCN9A | Beyond the Ion Channel
Pingback: G proteins, GNAO1 mutations and Ohtahara Syndrome | Beyond the Ion Channel
Pingback: Identifying core phenotypes – epilepsy, ID and recurrent microdeletions | Beyond the Ion Channel
Pingback: Infantile Spasms/Lennox-Gastaut genetics goes transatlantic | Beyond the Ion Channel
Pingback: 2B or not 2B – mutations in GRIN2B and Infantile Spasms | Beyond the Ion Channel
Pingback: Story of a genetic shape-shifter: SCN2A in benign seizures, autism and epileptic encephalopathy | Beyond the Ion Channel
Pingback: Modifier genes in Dravet Syndrome: where to look and how to find them | Beyond the Ion Channel
Pingback: TBC1D24, DOORS Syndrome, and the unexpected heterogeneity of recessive epilepsies | Beyond the Ion Channel
Pingback: Surrendering to genomic noise – de novo mutations in schizophrenia | Beyond the Ion Channel
Pingback: Publications of the week: genetics of Infantile Spasms, CERS1, DYRK1A, and hyaluronan | Beyond the Ion Channel